BMP Effect on Implant Stability and Marginal Bone Level After Immediate Placement

Evaluating the Effect of Bone Morphogenetic Protein on Dental Implant Stability and Marginal Bone Level Following Immediate Implant Placement (Randomized Controlled Study)

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07240493

Enrollment

Registered

2025-11-21

Start date

2024-12-15

Completion date

2026-01-15

Last updated

2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Ridge Resorption After Extraction, Tooth Extraction, Tooth Loss

Keywords

immediate implant placement, Bone morphogenetic protein, rhBMP-2

Brief summary

This randomized controlled clinical trial aims to evaluate the effect of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) on the stability and marginal bone level of dental implants following immediate placement. patients requiring extraction of unrestorable tooth in upper incisors or premolar region will be randomly assigned into two groups: the experimental group will receive immediate implant placement with rhBMP-2 application, while the control group will receive immediate implant placement without rhBMP-2. each group includes 16 immediate implants. Implant stability will be assessed using resonance frequency analysis (RFA) at baseline, and 16 weeks after implant placement. Marginal bone level changes will be evaluated radiographically using cone beam computed tomography (CBCT). The study aims to determine whether the use of rhBMP-2 enhances osseointegration and reduces marginal bone loss compared with conventional immediate implant placement.

Interventions

BIOLOGICALrhBMP-2 placement

rhBMP-2 is mixed with BCP bone graft and placed in the jumping gap after immediate dental implant placement.

DEVICEconventional immediate implant

Standard immediate dental implant placement procedure without adding of Bone Morphogenetic Protein in the bone graft placed in the jumping gap.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Healthy patients ≥18 years of either sex * Having a single or multiple unrestorable maxillary anterior and premolar teeth indicated for extraction * Jumping gap ≥2 mm * Apical bone ≥3 mm from the vertical structure beyond the apex * Willing to comply with the study and provide informed consent * Good oral hygiene

Exclusion criteria

* Active infection or inflammation in implant area * Uncontrolled diabetes or coagulation disorders * Immunocompromised patients * Patients treated with bisphosphonate drugs * Psychiatric problems * Pregnant women * Medical conditions affecting bone healing * Clinical evidence of parafunctional habits * Heavy smokers (≥20 cigarettes/day)

Design outcomes

Primary

Measure	Time frame	Description
Implant Stability Quotient (ISQ) measured by Resonance Frequency Analysis	Baseline and 16 weeks after implant placement	Evaluation of implant stability using resonance frequency analysis (RFA) device to measure the Implant Stability Quotient (ISQ) at baseline and 16 weeks after implant placement.

Secondary

Measure	Time frame	Description
Marginal Bone Level (MBL) Changes around Dental Implants	Baseline and 16 weeks after implant placement	Radiographic assessment of marginal bone level (MBL) around dental implants using Cone Beam Computed Tomography (CBCT) at baseline and 16 weeks after implant placement.

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026